These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28129639)

  • 1. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
    Kemp DM; Pidich A; Larijani M; Jonas R; Lash E; Sato T; Terai M; De Pizzol M; Allegretti M; Igoucheva O; Alexeev V
    Oncotarget; 2017 Feb; 8(9):14428-14442. PubMed ID: 28129639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
    Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
    Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
    Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
    Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
    Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.
    Varney ML; Singh S; Li A; Mayer-Ezell R; Bond R; Singh RK
    Cancer Lett; 2011 Jan; 300(2):180-8. PubMed ID: 21035946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.
    Sharma B; Singh S; Varney ML; Singh RK
    Expert Opin Ther Targets; 2010 Apr; 14(4):435-42. PubMed ID: 20230195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.
    Singh S; Sadanandam A; Nannuru KC; Varney ML; Mayer-Ezell R; Bond R; Singh RK
    Clin Cancer Res; 2009 Apr; 15(7):2380-6. PubMed ID: 19293256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
    Shang FM; Li J
    Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.
    Singh S; Sadanandam A; Varney ML; Nannuru KC; Singh RK
    Int J Cancer; 2010 Jan; 126(2):328-36. PubMed ID: 19585580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
    Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
    Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
    Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
    Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil.
    Wang J; Hu W; Wang K; Yu J; Luo B; Luo G; Wang W; Wang H; Li J; Wen J
    Int J Oncol; 2016 Apr; 48(4):1341-52. PubMed ID: 26847910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
    Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
    Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
    Tazzyman S; Barry ST; Ashton S; Wood P; Blakey D; Lewis CE; Murdoch C
    Int J Cancer; 2011 Aug; 129(4):847-58. PubMed ID: 21328342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
    Fu S; Chen X; Lin HJ; Lin J
    Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.
    Ruma IM; Putranto EW; Kondo E; Murata H; Watanabe M; Huang P; Kinoshita R; Futami J; Inoue Y; Yamauchi A; Sumardika IW; Youyi C; Yamamoto K; Nasu Y; Nishibori M; Hibino T; Sakaguchi M
    Clin Exp Metastasis; 2016 Aug; 33(6):609-27. PubMed ID: 27151304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M; Singh D
    J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.